Novogene announced that the company will hold a meeting on October 23, 2025, to review and approve the proposal for asset impairment provision. Based on the principle of prudence, the company assessed the relevant assets as of September 30, 2025, and the total impairment provision for this period is approximately RMB 24.5321 million, including credit impairment losses of RMB 24.3586 million and asset impairment losses of RMB 173,400. This will reduce the total pre-tax profit in the consolidated financial statements for the first three quarters of 2025 by RMB 24.5321 million, correspondingly reducing the owner's equity at the end of the reporting period. The data is unaudited and subject to the amount confirmed by the annual audit. Both the board of directors and the audit committee agreed to this provision
